
Opinion|Videos|November 28, 2023
Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial
Author(s)Hope S. Rugo, MD, FASCO
Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
2
Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL
3
FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations
4
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
5





















































